A group of researchers identified a genetic variation that would predict the chances of survival of women affected by breast cancer, particularly after a chemotherapy treatment, according to the specialist journal Nature Genetics.

Heli Nevanlinna (University of Helsinki, Finland), Jiri Bartek (Danish Cancer Society) and his colleagues conducted the first study of option “NQO1 * 2” as a factor in the prognosis for the treatment of breast cancer, according to his work published this Friday in the online edition of the magazine.

The researchers performed genetic analysis on more than 2,000 women in Finland, studying the disease and its treatment. The prognosis for breast cancer depends on factors like the state of the tumor, the presence or absence of hormone receptors, the excessive production of the protein HER2 (HER +) that favors the proliferation carcinogenic. These elements are used to tailor treatment to each patient, remind the authors of the study.

Thus, patients with HER2 may receive a drug adapted, Herceptin. But new indicators would be needed to find the chances of successful treatment, according to the authors.

The enzyme “NQ01” protects cells against oxidative stress that damages and accelerates their aging, and acts against the carcinogenic processes. But the “NQO1 * 2”-present in between 4% and 20% of people-is a common gene variation of the enzyme “NQ01” and has the peculiarity of eliminating the production of this protective enzyme.

According to the study, women who have two copies of this variant “NQO1 * 2” and receiving chemotherapy based anthracyclina, such as epirubicin, have a survival rate of only 17%.

Those patients who only have a copy of “NQO1 * 2” have a survival rate of 75%. Possessing two copies of the variant also reduces significantly the survival after metastasis of breast cancer, the authors stress.

Sources: Perfil

No related content found.